UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease

Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of in...

Descripción completa

Detalles Bibliográficos
Autores principales: Buka, Richard J, Roy, Noémi, Nicolson, Phillip LR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Sickle Cell, Thrombosis, and Classical Haematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928781/
https://www.ncbi.nlm.nih.gov/pubmed/36819149
http://dx.doi.org/10.1002/jha2.623
_version_ 1784888714822942720
author Buka, Richard J
Roy, Noémi
Nicolson, Phillip LR
author_facet Buka, Richard J
Roy, Noémi
Nicolson, Phillip LR
author_sort Buka, Richard J
collection PubMed
description Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet‐based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.
format Online
Article
Text
id pubmed-9928781
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99287812023-02-16 UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease Buka, Richard J Roy, Noémi Nicolson, Phillip LR EJHaem Sickle Cell, Thrombosis, and Classical Haematology Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet‐based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities. John Wiley and Sons Inc. 2022-12-25 /pmc/articles/PMC9928781/ /pubmed/36819149 http://dx.doi.org/10.1002/jha2.623 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Sickle Cell, Thrombosis, and Classical Haematology
Buka, Richard J
Roy, Noémi
Nicolson, Phillip LR
UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
title UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
title_full UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
title_fullStr UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
title_full_unstemmed UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
title_short UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
title_sort uk media reporting of nice recommendation of crizanlizumab for patients with sickle cell disease
topic Sickle Cell, Thrombosis, and Classical Haematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928781/
https://www.ncbi.nlm.nih.gov/pubmed/36819149
http://dx.doi.org/10.1002/jha2.623
work_keys_str_mv AT bukarichardj ukmediareportingofnicerecommendationofcrizanlizumabforpatientswithsicklecelldisease
AT roynoemi ukmediareportingofnicerecommendationofcrizanlizumabforpatientswithsicklecelldisease
AT nicolsonphilliplr ukmediareportingofnicerecommendationofcrizanlizumabforpatientswithsicklecelldisease

Ejemplares similares